Details of the Drug

General Information of Drug (ID: DMGQFYB)

• Drug Name: Mecamylamine
• Synonyms: Mecamilamina; Mecamine; Mecamylaminum; Mekamine; Mevasine; Revertina; Versamine; Inversine hydrochloride; Mecamilamina [DCIT]; Mecamilamina [Italian]; Mevasin hydrochloride; Inversine (TN); Mecamylamine [INN:BAN]; Mecamylaminum [INN-Latin]; N-Methyl-2-isocamphanamine; N,2,3,3-Tetramethyl-2-norbornamine; N,2,3,3-Tetramethyl-2-norcamphanamine; N,2,2,3-tetramethylbicyclo[2.2.1]heptan-3-amine; N,2,3,3-Tetramethylbicyclo[2.2.1]heptan-2-amine; 2-Methylamino-2,3,3-trimethylnorbornane; 2-Methylaminoisocamphane; 3-Methylaminoisocamphane; 3-Methylaminoisokamfan; 3-Methylaminoisokamfan [Czech]; 3-beta-Methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane

Indication

Disease Entry	ICD 11	Status	REF
Essential hypertension	BA00	Approved	[1]

• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 167.29
  Logarithm of the Partition Coefficient (xlogp); 2.6
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 1
• ADMET Property:
  Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [2]
  Elimination: 50% of drug is excreted from urine in the unchanged form [3]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.75245 micromolar/kg/day [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 212 mg/mL [3]
• Chemical Identifiers:
  Formula: C11H21N
  IUPAC Name: N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
  Canonical SMILES: CC1(C2CCC(C2)C1(C)NC)C
  InChI: InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3
  InChIKey: IMYZQPCYWPFTAG-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4032
  ChEBI ID: CHEBI:6706
  CAS Number: 60-40-2
  DrugBank ID: DB00657
  TTD ID: D0V8HA
  ACDINA ID: D00386

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nicotinic acetylcholine receptor (nAChR)	TTJSZTB	NOUNIPROTAC	Antagonist	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Contactin-1 (CNTN1)	OT7RNPEY	CNTN1_HUMAN	Gene/Protein Processing	[6]
Dihydrofolate reductase (DHFR)	OT3DVIGM	DYR_HUMAN	Gene/Protein Processing	[6]
Echinoderm microtubule-associated protein-like 4 (EML4)	OTJC45TA	EMAL4_HUMAN	Gene/Protein Processing	[6]
Fasciculation and elongation protein zeta-1 (FEZ1)	OTWCXPRE	FEZ1_HUMAN	Gene/Protein Processing	[6]
Golgin subfamily A member 4 (GOLGA4)	OTCMEHNJ	GOGA4_HUMAN	Gene/Protein Processing	[7]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF)	OTT5JX1F	LITAF_HUMAN	Gene/Protein Processing	[6]
Receptor-type tyrosine-protein phosphatase alpha (PTPRA)	OTZA82J1	PTPRA_HUMAN	Gene/Protein Processing	[6]
Stress-induced-phosphoprotein 1 (STIP1)	OT7TXLOX	STIP1_HUMAN	Gene/Protein Processing	[7]
Ubiquitin-protein ligase E3A	OTIA27P3	UBE3A_HUMAN	Gene/Protein Processing	[6]
Zinc finger RNA-binding protein	OTYDAOT8	ZFR_HUMAN	Gene/Protein Processing	[6]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mecamylamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Mecamylamine caused by Sodium bicarbonate mediated altered urine pH.	Acidosis [5C73]	[8]
Tromethamine	DMOBLGK	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Mecamylamine caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[8]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Cariprazine.	Bipolar disorder [6A60]	[9]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Selegiline.	Depression [6A70-6A7Z]	[10]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Isocarboxazid.	Depression [6A70-6A7Z]	[10]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Tranylcypromine.	Depression [6A70-6A7Z]	[10]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Mecamylamine and OPC-34712.	Depression [6A70-6A7Z]	[9]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Phenelzine.	Depression [6A70-6A7Z]	[10]
SODIUM CITRATE	DMHPD2Y	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Mecamylamine caused by SODIUM CITRATE mediated altered urine pH.	Discovery agent [N.A.]	[8]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Procarbazine.	Hodgkin lymphoma [2B30]	[10]
Sodium acetate anhydrous	DMH21E0	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Mecamylamine caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[8]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Propiomazine.	Insomnia [7A00-7A0Z]	[9]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Mecamylamine and ITI-007.	Insomnia [7A00-7A0Z]	[9]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Ozanimod.	Multiple sclerosis [8A40]	[10]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Promethazine.	Nausea/vomiting [MD90]	[9]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Safinamide.	Parkinsonism [8A00]	[10]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Rasagiline.	Parkinsonism [8A00]	[10]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[9]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Quetiapine.	Schizophrenia [6A20]	[9]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Mesoridazine.	Schizophrenia [6A20]	[9]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Thioridazine.	Schizophrenia [6A20]	[9]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Aripiprazole.	Schizophrenia [6A20]	[9]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Iloperidone.	Schizophrenia [6A20]	[9]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Paliperidone.	Schizophrenia [6A20]	[9]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Perphenazine.	Schizophrenia [6A20]	[9]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Molindone.	Schizophrenia [6A20]	[9]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Thiothixene.	Schizophrenia [6A20]	[9]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Trifluoperazine.	Schizophrenia [6A20]	[9]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Risperidone.	Schizophrenia [6A20]	[9]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Amisulpride.	Schizophrenia [6A20]	[9]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Asenapine.	Schizophrenia [6A20]	[9]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[9]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Mecamylamine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[11]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Quinoline yellow WS	E00309	24671	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Brushite	E00392	104805	Diluent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Mecamylamine 2.5 mg tablet	2.5 mg	Oral Tablet	Oral
Mecamylamine Hydrochloride 2.5mg tablet	2.5mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [3] BDDCS applied to over 900 drugs
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
• [6] Nicotine modulates the expression of a diverse set of genes in the neuronal SH-SY5Y cell line. J Biol Chem. 2003 May 2;278(18):15633-40.
• [7] Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
• [8] Allanby KD, Trounce JR "Excretion of mecamylamine after intravenous and oral administration." Br Med J 2 (1957): 1219-21. [PMID: 13472094]
• [9] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [10] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [11] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.